In a female patient with intermittent left‑sided rib pain, itching without rash, mild nausea, softer frequent stools, and a diagnosis of rheumatoid arthritis (previously labeled rheumatic arthritis), what is the appropriate workup and management plan?

Workup and Management for Rheumatoid Arthritis with Left-Sided Rib Pain and GI Symptoms

Your patient's left-sided rib pain with itching, mild nausea, and softer stools is most likely unrelated to rheumatoid arthritis itself and requires focused evaluation for alternative causes, while simultaneously initiating aggressive RA treatment with methotrexate as first-line therapy.

Immediate Diagnostic Clarification

First, confirm the diagnosis: rheumatoid arthritis (M05/M06) is completely different from rheumatic arthritis (I01.1, acute rheumatic fever). If the patient truly has rheumatoid arthritis with positive RF or anti-CCP antibodies and inflammatory polyarthritis, proceed with RA management. If this was a documentation error and the patient has neither condition, the entire treatment approach changes.

Evaluation of Current Symptoms

The constellation of left-sided rib pain, itching without rash, mild nausea, and softer stools is not a typical manifestation of rheumatoid arthritis. While RA can affect multiple organ systems 1, the specific symptom pattern described warrants investigation for:

• Gastrointestinal causes: The CT scan you ordered is appropriate to evaluate pancreas, spleen, and adjacent structures
• Musculoskeletal causes: Costochondritis or intercostal muscle strain (though the itching is atypical)
• Neurological causes: Herpes zoster sine herpete (itching preceding pain in dermatomal distribution, even without visible rash)
• Medication-related effects: If the patient is already on methotrexate or other DMARDs, GI symptoms are common side effects 2

Critical Pitfall to Avoid

Do not attribute every symptom to RA. Rheumatoid vasculitis can rarely involve the GI tract 3, but this typically occurs in long-standing, severe RA with high disease activity—not as a presenting feature. The case report 3 describes a patient with hematemesis and erosive gastroduodenitis from leukocytoclastic vasculitis, which is far more severe than your patient's mild symptoms.

Rheumatoid Arthritis Management

Regardless of the rib pain etiology, if your patient has confirmed RA, initiate disease-modifying antirheumatic drug (DMARD) therapy immediately 2.

First-Line Treatment

Start methotrexate as the preferred initial DMARD 2, 4:

• Begin with oral methotrexate 15-25 mg weekly with folic acid supplementation 5
• If GI intolerance develops (which could explain or worsen her nausea), switch to subcutaneous methotrexate, which has higher bioavailability and significantly reduces GI side effects 2
• Consider short-term, low-dose glucocorticoids (e.g., prednisone 5-10 mg daily) only during DMARD initiation, then taper rapidly 2, 4

Pre-Treatment Requirements

Before starting methotrexate:

• Complete blood count, liver function tests, creatinine
• Hepatitis B and C screening
• Tuberculosis screening (interferon-gamma release assay or PPD)
• Pregnancy test if applicable
• Update vaccinations before starting immunosuppression 2, 6

Monitoring and Treatment Goals

• Treat-to-target strategy: Aim for remission or low disease activity 2, 5
• Assess disease activity every 3 months using validated indices (DAS28, CDAI, or SDAI)
• If inadequate response after 3-6 months of optimized methotrexate, escalate to:
  • Triple conventional synthetic DMARD therapy (methotrexate + sulfasalazine + hydroxychloroquine) for patients without poor prognostic factors 2
  • OR add a biologic DMARD (TNF inhibitor, IL-6 inhibitor, abatacept, or rituximab) 2, 4
  • JAK inhibitors are an option but should be used cautiously in patients ≥65 years with cardiovascular risk factors or smoking history due to increased risk of MACEs and malignancies 2, 4

Addressing the Current Symptom Complex

Given the temporal relationship between softer stools and the onset of pain, plus the itching:

1. Complete the CT scan to rule out structural pathology
2. Consider dermatology referral if itching persists without rash—could represent neuropathic itch or early shingles
3. Monitor for rash development over the next week
4. If methotrexate is started and GI symptoms worsen, switch to subcutaneous formulation immediately 2

Cardiovascular Risk Management

Patients with RA have cardiovascular risk equivalent to diabetes mellitus 1. Address:

• Blood pressure control (already monitoring)
• Lipid screening and management
• Smoking cessation if applicable
• Regular cardiovascular risk assessment

Non-Pharmacological Management

Integrate into comprehensive care 2, 7:

• Patient education about RA and treatment expectations
• Regular physical activity and exercise programs
• Multidisciplinary approach including physical therapy
• Psychological support for chronic disease management

The key distinction here is separating RA management (which should proceed aggressively with methotrexate) from evaluation of symptoms that are likely unrelated to RA but require their own diagnostic workup.